Dirican A., Aktaş S., Aktaş T. Ç., Erol A., Gökbayrak Ö., Kolatan H. E., ...Daha Fazla
Teod, Haziran 2022
-
Ödülün Kapsamı:
Bilimsel/Mesleki Çalışmalardan Alınan Ödül
-
Ödül Türü:
Kongre, Konferans, Festival veya Sempozyum Kurullarınca Verilen Ödül
-
Ödül Veren Ülke:
Türkiye
-
Ödülü Veren Organizasyon:
Teod
-
Araştırma Alanları:
Tıp, Sağlık Bilimleri
-
Ödülün Tarihi:
Haziran 2022
-
Açıklama:
<p>EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB
ON EXPERIMENTAL RENAL CELL CANCER MODELS
Ahmet DİRİCAN1
, Safiye AKTAŞ2
, Tekincan AKTAŞ2
, Aylin EROL2
, Özde GÖKBAYRAK2
, Efsun KOLATAN3
,
Efe SERİNAN2
, Zekiye Sultan ALTUN2
, Işıl SOMALI4
, Osman YILMAZ3
1
Izmir Economy University, Medical Park Hospital, Department of Medical Oncology, Izmir, Turkiye
2
Dokuz Eylul University, Institute of Oncology, Department of Basic Oncology, Izmir, Turkiye
3
Dokuz Eylul University, Department of Experimental Animal Sciences, Izmir, Turkiye
4
Dokuz Eylul University, Institute of Oncology, Department of Clinical Oncology, Izmir, Turkiye
POSTER PRESENTATION ABSTRACTS
Journal of Advanced Research in Health Sciences /
Sağlık Bilimlerinde İleri Araştırmalar Dergisi 2022
DOI: 10.26650/JARHS2021-1133817 [PP-014]
This work is licensed under Creative Commons Attribution-NonCommercial 4.0 International License
ABSTRACT
Objectives: Thymoquinone a bioactive component extracted from the seeds of Nigella sativa, has been proved to have antiinflammatory, antioxidant
properties anti antitumor efficiency against breast, prostate, bladder, and renal cell cancer. We aimed to investigate the synergistic cytotoxic and apoptotic
effects of thymoquinone in combination with nivolumab, an immuno-control inhibitor, and its mechanism in renal cell cancer models.
Materials and Methods: In vitro studies: Caki-1 and Renca renal cancer cell lines with mononuclear cells were cocultured and thymoquinone and
nivolumab effect were analyzed by MTT and Annexin V + PI. In vivo studies: Renal cell cancer model was provided by subcutaneous injection of RENCA
cells to C57BL/6, male, 8 weeks old mice in four groups. Control group, thymoquinone (1,4,7,14days,20mg/kgIP), nivolumab administered (1,6,13days10mg/
kgIP), thymoquinone and nivolumab. Seven animals was randomized in each experimental group. Apoptosis, necrosis, CD4,CD8,C20,CD34,CD31,VEGF-A by
immunohistochemistry, FGFR-1,PDGFRbeta,VEGFR-2,c-kit,RET,c-Met,AXL,Flt-3,TIE2, ICAM-1,VCAM-1 and E-selectin mRNA levels by quantitative real-timePCR were evaluated on tumor tissue. Liver, kidney, brain, lung and heart tissues was evaluated for side effects. Plasma biochemistry tests were performed.
Statistical analysis was be performed with Mann-Whitney U test with p <0.05 value.
Results: Thymoquinone showed antitumor effect in vitro and in vivo. It also showed increase in immune cell death of nivolumab. Tumor tissue showed
prominent necrosis or complete response to therapy in combination group.
Conclusions: We conclude that thymoquinone has antitumor effect on renal cell carcinoma and increases the effect of nivolumab immune, cell death
effects. Besides, it does not have side effect on other organs whether alone or in combination.
Keywords: Renal Cell Cancer, Thymoquinone, Immune Check Point Inhibitors<br></p>